Indapamide-CRCa sustained release pills 1.5mg, 30pcs

Composition

1 tab. contains indapamide 1.5 mg

Pharmacological action

Thiazide-like diuretic, antihypertensive agent. It causes a decrease in arterial smooth muscle tone, a decrease in OPSS, and also has moderate saluretic activity due to impaired reabsorption of sodium, chlorine, and water ions in the cortical segment of the Henle loop and the proximal convoluted tubule of the nephron.

The decrease in OPSS is caused by several mechanisms: a decrease in the sensitivity of the vascular wall to norepinephrine and angiotensin II; an increase in the synthesis of prostaglandins with vasodilating activity; inhibition of the influx of calcium ions into the smooth muscle elements of the vascular wall. In therapeutic doses, it has almost no effect on lipid and carbohydrate metabolism.

The antihypertensive effect is manifested only with initially elevated blood pressure, develops by the end of the first week and reaches a maximum after 3 months of systematic use.

Indications

Arterial hypertension; sodium and water retention in chronic heart failure.

Contraindications

Acute cerebrovascular accident, severe renal and/or hepatic dysfunction, severe forms of diabetes mellitus and gout, hypersensitivity to indapamide.

Side effects

From the digestive system:  nausea, feeling of discomfort or pain in the epigastrium.

From the central nervous system:  weakness, fatigue, dizziness, nervousness.

From the cardiovascular system:  orthostatic hypotension.

From the side of metabolism:  hypokalemia, hyperuricemia, hyperglycemia, hyponatremia, hypochloremia.

Allergic reactions:  skin manifestations.

Interaction

With the simultaneous use of corticosteroids, tetracosactide for systemic use, the hypotensive effect decreases due to the retention of water and sodium ions under the influence of corticosteroids.

When used concomitantly with ACE inhibitors, the risk of hyponatremia increases.

When used concomitantly with NSAIDs (for systemic use), the hypotensive effect of indapamide may decrease. With significant fluid loss, acute renal failure may develop (due to a sharp decrease in glomerular filtration).

When used concomitantly with calcium preparations, hypercalcemia may develop due to a decrease in the excretion of calcium ions in the urine.

When used concomitantly with cardiac glycosides, corticosteroids, the risk of hypokalemia increases.

Concomitant use of drugs that can cause hypokalemia (amphotericin B, gluco-and mineralocorticoids, tetracosactide, laxatives that stimulate intestinal motility) increases the risk of hypokalemia.

When used concomitantly with tricyclic antidepressants (including imipramine), the hypotensive effect increases and the risk of orthostatic hypotension increases (additive effect).

When used concomitantly with astemizole, bepridil, erythromycin (IV), pentamidine, sultoprid, terfenadine, vincamine, quinidine, disopyramide, amiodarone, bretilia tosilate, sotalol, there is a risk of developing arrhythmia of the “pirouette” type.

When used concomitantly with baclofen, the hypotensive effect increases.

When used concomitantly with halofantrine, the likelihood of heart rhythm disorders (including ventricular arrhythmia of the “pirouette” type) increases.

When used concomitantly with lithium carbonate, the risk of developing a toxic effect of lithium increases against the background of a decrease in its renal clearance.

Concomitant use with metformin may cause lactic acidosis, which is probably associated with the development of functional renal failure due to the action of diuretics (mainly “loop”).

When used concomitantly with cyclosporine, it is possible to increase the content of creatinine in blood plasma, which is observed even with a normal content of water and sodium ions.

How to take, course of use and dosage

Take orally 2.5 mg 1 time/day (in the morning). If the hypotensive effect is not sufficiently pronounced after 2 weeks of treatment, the dose is increased to 5-7.5 mg / day.

The maximum daily dose is 10 mg, divided into 2 doses (in the morning).

Special instructions

It is used with caution in patients with diabetes mellitus (glucose control is necessary, especially in the presence of hypokalemia), gout (an increase in the number of attacks is possible), in patients with a history of allergic reactions to sulfonamide derivatives.

During treatment, it is necessary to monitor the level of electrolytes in the blood plasma (potassium, sodium, calcium).

Active ingredient

Indapamide

Conditions of release from pharmacies

By prescription

Dosage form

long-acting tablets